HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA Carcinogenicity Evidence Limited To "One Study, One Species" - CTFA

This article was originally published in The Rose Sheet

Executive Summary

Animal data indicating diethanolamine may be a human carcinogen are limited to "one study in one species, with...one route of exposure," the Cosmetic, Toiletry and Fragrance Association maintains in Sept. 17 comments to the National Toxicology Program.

You may also be interested in...



DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

Transgenic Mouse Model Can Complement Carcinogenicity Testing, NTP Says

At the present time, the transgenic mouse model test method should be used as a complement to the traditional two-year rodent bioassay as a tool for carcinogen identification, the National Toxicology Program Board of Scientific Counselors recommended

Related Content

UsernamePublicRestriction

Register

RS009661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel